Precision Diagnostic Approach, When Minutes And Complete Information Matter
In emergency, trauma, critical care settings, rapid diagnosis of bleeding and clotting risk and restoration of hemostasis can mean the difference between life and death
FloBio a 2022 Semi-Finalist in AACC Disruptive Technology Competition and attending AACC
JULY 24-28 CHICAGO, IL
2022 AACC ANNUAL SCIENTIFIC MEETING + CLINICAL LAB EXPO
Vision
To transform emergency critical care patient management by providing clinicians rapid, actionable information that enables optimal decision making and cost effective management of blood clotting abnormalities or serious bleeding.
“FloBio is developing an exciting POC lab test with wide applicability. This novel assay would have applicability for patients taking or suspected of taking DOACs as well as patients with a concern for coagulopathy or those with active bleeding requiring a guided resuscitation. The results of this test would guide treatment, including DOAC reversal strategies, and bring clarity and value to what has been a nebulous space to date, due to the void of adequate testing.”
Dr. Niels D. Martin, Section Chief, Surgical Critical Care; Department of Surgery at the University of Pennsylvania’s School of Medicine
Novel Point-of-Care Fluidic Based Diagnostic Platform
MultiPlex analysis of flowing blood. Real time evaluation of hemostasis function. Actionable Information.
Developing With Clinicians And Hospitals In Mind
Early Risk Assessment
Quick Decisions
Cost Effectiveness
Patient Outcomes
Rooted In Innovation
Proven Scientific Platform
Founded >10 years of research. Residing at the state of the art Pennovation Center in Philadelphia
Latest News
FDA grants FloBio Breakthrough Device Designation
For Bleeding Risk Diagnostic Test
Publications
Developing a Portfolio of Tests
Our 1st test in development designed to evaluate Direct Oral Anti-coagulant drug presence, class and level
